{"id":724,"date":"2026-09-01T15:21:54","date_gmt":"2026-09-01T15:21:54","guid":{"rendered":"https:\/\/nhdbio.com\/case-studies\/cjc-1295-dac-randomized-human-pharmacology\/"},"modified":"2026-09-01T15:32:23","modified_gmt":"2026-09-01T15:32:23","slug":"cjc-1295-dac-randomized-human-pharmacology","status":"publish","type":"case_study","link":"https:\/\/nhdbio.com\/de\/case-studies\/cjc-1295-dac-randomized-human-pharmacology\/","title":{"rendered":"CJC-1295 mit DAC: Randomisierte Humanpharmakologie und die Albumin-Bindungsgrenze"},"content":{"rendered":"<h2>Die Identit\u00e4tsfrage kommt vor dem Ergebnis<\/h2>\n<p>Die genannte Verbindung wurde als langwirksames GHRH-Analogon entwickelt, das endogenes Albumin bindet. Dieses Designmerkmal ist f\u00fcr die pharmakokinetische Frage von zentraler Bedeutung. Suchseiten fassen h\u00e4ufig \u201emit DAC\u201c und \u201eohne DAC\u201c in einem Namen zusammen, aber dadurch \u00e4ndert sich die molekulare Identit\u00e4t und eine direkte \u00dcbertragung der gemeldeten Halbwertszeit wird ung\u00fcltig.<\/p>\n<h2>Was bei den Versuchen gemessen wurde<\/h2>\n<p>Die beiden Studien waren randomisiert, placebokontrolliert, doppelblind und dosissteigernd. Ihre Hauptergebnisse waren die zirkulierende GH- und IGF-I-Exposition sowie pharmakokinetische Parameter. Das sind pharmakologische Endpunkte. Sie sind kein direktes Ma\u00df f\u00fcr eine verbesserte Gesundheit, K\u00f6rperzusammensetzung oder Leistung.<\/p>\n<h2>Der gemeldete Zeitverlauf<\/h2>\n<p>Die Autoren berichteten von anhaltenden, dosisabh\u00e4ngigen GH- und IGF-I-Anstiegen und einer gesch\u00e4tzten Halbwertszeit, gemessen in Tagen. Eine begleitende Studie berichtete, dass die pulsierende GH-Sekretion auch unter dem anhaltenden Reiz beobachtbar blieb. Diese Aufzeichnungen unterst\u00fctzen eine mechanistische und zeitliche Diskussion nur f\u00fcr das DAC-Formular.<\/p>\n<div class=\"pfm-case-callout\"><strong>Namenspr\u00fcfung:<\/strong> Eine Seite, die den klassischen CJC-1295-Test verwendet, um \u201eCJC-1295 ohne DAC\u201c zu beschreiben, vermischt zwei unterschiedliche Materialien. Die Produktidentit\u00e4t muss mit der zitierten Intervention \u00fcbereinstimmen, bevor eine Nummer wiederverwendet wird.<\/div>\n<h2>Was die Studie nicht beweist<\/h2>\n<p>Kurze Hormon- und Expositionsdaten in der Fr\u00fchphase belegen weder die therapeutische Wirksamkeit noch die Langzeitsicherheit noch die Qualit\u00e4t einer kommerziellen Charge. F\u00fcr eine aktuelle Charge ist eine eigene Identit\u00e4ts-, Untersuchungs- und Freigabedokumentation erforderlich. Die Literatur kann diese Kontrollen nicht ersetzen.<\/p>","protected":false},"excerpt":{"rendered":"<p>Eine genaue Lekt\u00fcre der beiden randomisierten Studien mit ansteigender Dosis bei gesunden Erwachsenen mit Schwerpunkt auf den Zeitverl\u00e4ufen von GH und IGF-I, der gesch\u00e4tzten Halbwertszeit und der Frage, warum die Ergebnisse nicht auf CJC-1295 ohne DAC zutreffen.<\/p>","protected":false},"author":0,"featured_media":852,"template":"","class_list":["post-724","case_study","type-case_study","status-publish","has-post-thumbnail","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.0 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CJC-1295 DAC Human Trial: GH, IGF-I and Half-Life<\/title>\n<meta name=\"description\" content=\"A close reading of the two randomized ascending-dose studies in healthy adults, focusing on GH and IGF-I time courses, estimated half-life and why the findings do not apply to CJC-1295 without DAC.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/de\/case-studies\/cjc-1295-dac-randomized-human-pharmacology\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CJC-1295 With DAC: Randomized Human Pharmacology and the Albumin-Binding Boundary\" \/>\n<meta property=\"og:description\" content=\"A close reading of the two randomized ascending-dose studies in healthy adults, focusing on GH and IGF-I time courses, estimated half-life and why the findings do not apply to CJC-1295 without DAC.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/de\/case-studies\/cjc-1295-dac-randomized-human-pharmacology\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-01T15:32:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/cjc-1295-dac-editorial-v2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1672\" \/>\n\t<meta property=\"og:image:height\" content=\"941\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data1\" content=\"1\u00a0Minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/cjc-1295-dac-randomized-human-pharmacology\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/cjc-1295-dac-randomized-human-pharmacology\\\/\",\"name\":\"CJC-1295 DAC Human Trial: GH, IGF-I and Half-Life\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/cjc-1295-dac-randomized-human-pharmacology\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/cjc-1295-dac-randomized-human-pharmacology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/cjc-1295-dac-editorial-v2.webp\",\"datePublished\":\"2026-09-01T15:21:54+00:00\",\"dateModified\":\"2026-09-01T15:32:23+00:00\",\"description\":\"A close reading of the two randomized ascending-dose studies in healthy adults, focusing on GH and IGF-I time courses, estimated half-life and why the findings do not apply to CJC-1295 without DAC.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/cjc-1295-dac-randomized-human-pharmacology\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/cjc-1295-dac-randomized-human-pharmacology\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/cjc-1295-dac-randomized-human-pharmacology\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/cjc-1295-dac-editorial-v2.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/cjc-1295-dac-editorial-v2.webp\",\"width\":1672,\"height\":941,\"caption\":\"Editorial laboratory illustration; not an image of a supplied lot or a reported analytical result.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/cjc-1295-dac-randomized-human-pharmacology\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u6848\u4f8b\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"CJC-1295 With DAC: Randomized Human Pharmacology and the Albumin-Binding Boundary\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CJC-1295 DAC Humanversuch: GH, IGF-I und Halbwertszeit","description":"Eine genaue Lekt\u00fcre der beiden randomisierten Studien mit ansteigender Dosis bei gesunden Erwachsenen mit Schwerpunkt auf den Zeitverl\u00e4ufen von GH und IGF-I, der gesch\u00e4tzten Halbwertszeit und der Frage, warum die Ergebnisse nicht auf CJC-1295 ohne DAC zutreffen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/de\/case-studies\/cjc-1295-dac-randomized-human-pharmacology\/","og_locale":"de_DE","og_type":"article","og_title":"CJC-1295 With DAC: Randomized Human Pharmacology and the Albumin-Binding Boundary","og_description":"A close reading of the two randomized ascending-dose studies in healthy adults, focusing on GH and IGF-I time courses, estimated half-life and why the findings do not apply to CJC-1295 without DAC.","og_url":"https:\/\/nhdbio.com\/de\/case-studies\/cjc-1295-dac-randomized-human-pharmacology\/","og_site_name":"NHD","article_modified_time":"2026-09-01T15:32:23+00:00","og_image":[{"width":1672,"height":941,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/cjc-1295-dac-editorial-v2.webp","type":"image\/webp"}],"twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"Gesch\u00e4tzte Lesezeit":"1\u00a0Minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/case-studies\/cjc-1295-dac-randomized-human-pharmacology\/","url":"https:\/\/nhdbio.com\/case-studies\/cjc-1295-dac-randomized-human-pharmacology\/","name":"CJC-1295 DAC Humanversuch: GH, IGF-I und Halbwertszeit","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/case-studies\/cjc-1295-dac-randomized-human-pharmacology\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/case-studies\/cjc-1295-dac-randomized-human-pharmacology\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/cjc-1295-dac-editorial-v2.webp","datePublished":"2026-09-01T15:21:54+00:00","dateModified":"2026-09-01T15:32:23+00:00","description":"Eine genaue Lekt\u00fcre der beiden randomisierten Studien mit ansteigender Dosis bei gesunden Erwachsenen mit Schwerpunkt auf den Zeitverl\u00e4ufen von GH und IGF-I, der gesch\u00e4tzten Halbwertszeit und der Frage, warum die Ergebnisse nicht auf CJC-1295 ohne DAC zutreffen.","breadcrumb":{"@id":"https:\/\/nhdbio.com\/case-studies\/cjc-1295-dac-randomized-human-pharmacology\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/case-studies\/cjc-1295-dac-randomized-human-pharmacology\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/nhdbio.com\/case-studies\/cjc-1295-dac-randomized-human-pharmacology\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/cjc-1295-dac-editorial-v2.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/cjc-1295-dac-editorial-v2.webp","width":1672,"height":941,"caption":"Editorial laboratory illustration; not an image of a supplied lot or a reported analytical result."},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/case-studies\/cjc-1295-dac-randomized-human-pharmacology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"\u6848\u4f8b","item":"https:\/\/nhdbio.com\/case-studies\/"},{"@type":"ListItem","position":3,"name":"CJC-1295 With DAC: Randomized Human Pharmacology and the Albumin-Binding Boundary"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Peptidrohstoffe und individuelle Peptidsynthese","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/case_study\/724","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/case_study"}],"about":[{"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/types\/case_study"}],"version-history":[{"count":1,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/case_study\/724\/revisions"}],"predecessor-version":[{"id":729,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/case_study\/724\/revisions\/729"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/media\/852"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/media?parent=724"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}